Apellis’s Pegcetacoplan received FDA orphan designation as a treatment of amyotrophic lateral sclerosis, according to a post to the agency’s website. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Apellis presents Phase 3 functional analyses of SYFOVRE for geographic atrophy
- Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
- Apellis announces validation for four marketing applications for pegcetacoplan
- Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy